RxDoctor Payments Data

Hoi Yuen

Urogynecology and Reconstructive Pelvic Surgery · Greensboro, NCNPI 1104260439

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (46.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Intuitive Surgical at 44.9% of the total. Reporting peaked in 2021 at $5,489 and has fallen 88.8% since, to $617 in 2025.

$8,994in general payments, 2019–2025

Across 95 payments — averaging $94.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • Medtronic$2K
  • Axonics, Inc.$1K
  • Boston Scientific$363
  • Caldera Medical, Inc$343
  • Astellas Pharma US Inc$301
  • plus $903 from 13 others

What the payments were for

  • Travel & lodging$2,01722%
  • Food & beverage$2,69130%
  • Education$4,18246%
  • Gifts$1051%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,994 in reported general payments places this provider in the 65th percentile of 35 urogynecology and reconstructive pelvic surgery providers in North Carolina.

See all urogynecology and reconstructive pelvic surgery providers in North Carolina

Medicare billing

Part B allowed, 2024
$15,760
Medicare patients
85
Services billed
309

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron184$127,690
MyrbetriqMirabegron81$50,858
Estradiol158$10,373
PremarinEstrogens, Conjugated12$5,199
Trospium Chloride ErTrospium Chloride19$3,375
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst13$122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$185$127,690184 claims
Astellas Pharma US IncMyrbetriq$301$50,85881 claims
PfizerPremarin$19$5,19912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 35 urogynecology and reconstructive pelvic surgery providers in North Carolina.

Other urogynecology and reconstructive pelvic surgery in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →